ASX Share rice
Mon 17 May 2021 - 10:51:am (Sydney)

MYX Share Price

MAYNE PHARMA GROUP LIMITEDMYXPharmaceuticals, Biotechnology & Life Sciences

MYX Company Information

Name:

Mayne Pharma Group Limited

Sector:

Healthcare

Industry:

Drug Manufacturers-General

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

1538 Main North Road Salisbury South SA Australia 5106

Phone:

61 8 8209 2666

MD, CEO & Exec. Director:

Mr. Scott Anthony Richards

Chief Financial Officer:

Mr. Peter Paltoglou

Pres of International Operations:

Mr. Stefan J. Cross

VP of Investor Relations & Communications:

Ms. Lisa Pendlebury

Exec. VP & Gen. Counsel:

Ms. Kate Rintoul

VP of Group HR:

Dr. Andrew O. Herdman Ph.D.

Exec. VP of Specialty Products Division:

Mr. Brant Schofield

Exec. VP of Generics Products Division:

Mr. Daniel Moore

Chief Medical Officer:

Mr. Gerard G. Nahum M.D.

Exec. VP of Women's Health:

Mr. Donald Pearl

Company Overview:

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. The company operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. It also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

MYX Share Price Information

Shares Issued:

1.68B

Market Capitalisation:

$638.05M

Revenue (TTM):

$438.68M

Revenue Per Share (TTM):

$0.28

Earnings per Share:

$-0.19

Profit Margin:

-0.5833

Operating Margin (TTM):

$-0.03

Return On Assets (TTM):

$-0

Return On Equity (TTM):

$-0.27

Quarterly Revenue Growth (YOY):

-0.081

Gross Profit(TTM):

$211.52M

Diluted Earnings Per Share (TTM):

$-0.165

MYX CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-55,873,000

Change To Liabilities:

$-26,304,000

Total Cashflow From Investing Activities:

$-55,873,000

Net Borrowings:

$4.45M

Net Income:

$-92,789,000

Total Cash From Operating Activities:

$99.78M

Depreciation:

$80.40M

Other Cashflow From Investing Activities:

$-8,755,000

Change To Inventory:

$13.08M

Change To Account Receivables:

$67.51M

Sale Purchase Of Stock:

$72K

Capital Expenditures:

$8.99M

MYX Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-135,367,000

Net Income:

$-92,789,000

Gross Profit:

$234.58M

Operating Income:

$-135,367,000

Interest Expense:

$10.53M

Income Tax Expense:

$-40,832,000

Total Revenue:

$457.77M

Cost Of Revenue:

$223.19M

MYX Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$0.94B

Total Liabilities:

$787.63M

Total Stockholder Equity:

$1.04B

Other Current Liabilities:

$70.60M

Total Assets:

$1.83B

Common Stock:

$1.24B

Other Current Assets:

$409K

Retained Earnings:

$-350,640,000

Other Liabilities:

$210.40M

Good Will:

$22.17M

Other Assets:

$174.40M

Cash:

$137.79M

Total Current Liabilities:

$219.25M

Short-Term Debt:

$41.23M

Property - Plant & Equipment:

$238.24M

Net Tangible Assets:

$115.96M

Total Current Assets:

$490.95M

Long-Term Debt:

$344.42M

Net Receivables:

$233.27M

Short-Term Investments:

$1.33B

Inventory:

$94M

Accounts Payable:

$29.84M

Short-Term Investments:

$1.33

Non Current Liabilities (Other):

$180.23M

Non Current Liabilities Total:

$563.61M

MYX Share Price History

MYX News

26 Mar, 2021
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Mayne Pharma Group...
04 Mar, 2021
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the commercial launch of a generic version of ORTHO-CEPT® (desogestrel and ethinyl estradiol 0.15 mg / 0.03 mg) tablets to customers in the US.
09 Feb, 2021
If you want to know who really controls Mayne Pharma Group Limited ( ASX:MYX ), then you'll have to look at the makeup...
03 Jan, 2021
Mayne Pharma Group Limited ( ASX:MYX ) is possibly approaching a major achievement in its business, so we would like to...
14 Oct, 2020
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Mayne Pharma Group...
09 Sep, 2020
Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...
27 Jul, 2020
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the US Food and Drug Administration (FDA) has granted approval of its Abbreviated New Drug Application (ANDA) for chlorzoxazone tablet, 375 mg, 500 mg and 750 mg, in the United States. Mayne Pharma has commenced commercial launch activities to customers in the US.
21 Jul, 2020
A look at the shareholders of Mayne Pharma Group Limited (ASX:MYX) can tell us which group is most powerful. Insiders...
24 Jun, 2020
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021.
28 May, 2020
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has entered into an exclusive long-term license and supply agreement with Mithra Pharmaceuticals SA (Mithra) to commercialise E4/DRSP, a combined oral contraceptive, in Australia.
22 May, 2020
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of butalbital acetaminophen and caffeine (BAC) capsule 50mg/300mg/40mg in the United States. Mayne Pharma received approval from the US Food and Drug Administration for its Abbreviated New Drug Application, which is indicated for the treatment of tension headache (migraine).

MYX Dividend Payments

EX-Date Dividend Amount
2010-10-25$0.0143
2011-03-03$0.0072